[The contribution of dialysis and laboratoristic methods for the control of phosphates]
- PMID: 24777923
[The contribution of dialysis and laboratoristic methods for the control of phosphates]
Abstract
Prevention and correction of hyperphosphatemia is the first main goal of CKD-MBD management. Therefore, special attention is required to prevent a positive phosphate balance. In addition to a careful use of phosphate binders and dietary, phosphate control is needed to optimize the control of phosphate balance. In well-nourished patients is necessary to provide an optimal dialysis removal schedule. A solution could be the increase of the number of dialysis sessions per week and to carry out longer dialysis session strategies. Nevertheless, many patients have a high phosphate (P) intake linked to the high dietary protein requirement of dialysis patients, hence the use of intestinal P binders is mandatory to reduce P net intestinal absorption. Unfortunately the phosphate molecule must be considered as a medium molecular toxin. Nowadays it remains difficult to remove with modern dialysis strategies and ones clearance is still dependent on dialysis time. The best solutions are: hemodiafiltration with high-volume reinfusion, daily dialysis, long dialysis and modern peritoneal dialysis. Today, this scheduled strategies are difficult because of logistic and cost problems. However the milestone will be an adequate nutrition surveillance, especially with nursing collaboration toward dialysis treatments. This strategy should start in outpatient pre-dialysis ambulatory.
Similar articles
-
Phosphate control in dialysis.Int J Nephrol Renovasc Dis. 2013 Oct 4;6:193-205. doi: 10.2147/IJNRD.S35632. Int J Nephrol Renovasc Dis. 2013. PMID: 24133374 Free PMC article. Review.
-
Phosphate elimination in modalities of hemodialysis and peritoneal dialysis.Blood Purif. 2010;29(2):137-44. doi: 10.1159/000245640. Epub 2010 Jan 8. Blood Purif. 2010. PMID: 20093819 Review.
-
[Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].G Ital Nefrol. 2010 Nov-Dec;27 Suppl 52:S47-54. G Ital Nefrol. 2010. PMID: 21132662 Italian.
-
Management of hyperphosphatemia.Hemodial Int. 2006 Oct;10(4):338-45. doi: 10.1111/j.1542-4758.2006.00126.x. Hemodial Int. 2006. PMID: 17014508 Review.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical